3010 related articles for article (PubMed ID: 27079802)
1. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Topalian SL; Taube JM; Anders RA; Pardoll DM
Nat Rev Cancer; 2016 May; 16(5):275-87. PubMed ID: 27079802
[TBL] [Abstract][Full Text] [Related]
2. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
3. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
6. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
7. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
8. β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.
El Khatib MM; Sakuma T; Tonne JM; Mohamed MS; Holditch SJ; Lu B; Kudva YC; Ikeda Y
Gene Ther; 2015 May; 22(5):430-8. PubMed ID: 25786871
[TBL] [Abstract][Full Text] [Related]
9. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
Diesendruck Y; Benhar I
Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Day D; Hansen AR
BioDrugs; 2016 Dec; 30(6):571-584. PubMed ID: 27848165
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Buchbinder E; Hodi FS
J Clin Invest; 2015 Sep; 125(9):3377-83. PubMed ID: 26325034
[TBL] [Abstract][Full Text] [Related]
17. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
18. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.
Kourie HR; Awada G; Awada A
Immunotherapy; 2017 Jun; 9(8):647-657. PubMed ID: 28653570
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Advanced Lung Cancer.
Asmar R; Rizvi NA
Cancer J; 2015; 21(5):383-91. PubMed ID: 26389763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
